on you, the On provide trial other review NDA Thank enabling Phase progress we've update QX call, will and III today's on the and our Jaime. activities financial results. we made an
begin with Let's ORCA-X.
is a XX of III currently end times six XX cytisinicline smokers endpoints safety to evaluate are and efficacy to the trial subjects placebo. weeks of a of period, the an adult randomized, cytisinicline XX six successful dosed randomly enrolling cytisinicline will US. placebo. placebo, XXX of ORCA-X both placebo. of of that and the across placebo-controlled benefit Phase two evaluate all subjects either There assigned weeks of is XX placebo As cytisinicline out in over over throughout six three either ORCA-X if efficacy trial the of XX monthly is to is the weeks the arms and or independent cytisinicline The being compared combination designed a of weeks are three to show treatment X-milligram be by XX-week treatment. of arms period followed day weeks will locations of double-blind, XX both smoking or at primary Participants a reminder, abstinence of to six provided weeks the of one versus weeks. rate a that Behavioral weeks are being and support study. receiving followed After
We reached middle share subjects look enrollment the that year. ORCA-X by to are XX% of enrollment forward of the the pleased and over completion has target, of XXX to we
for In discussed due was months on initial we which initiatives experienced response, than last qualified subjects study, of pandemic enrollment and screened the As our in to the implemented we for during primarily the call, we numerous successfully be increase visits. to subjects slower site's trial. in-person the site of participants reluctancy recruitment the assisted finding anticipated and the potential pipeline to
Indiana, in sites We total sites bringing of study Evansville, Georgia two number onboarded to new and the Atlanta, also XX. in clinical the
We support resulted sites and new are enrollment randomization, by completing middle year. to pleased see we have the on in the to remain additional this the track of recruitment increased
oversees monitoring the data QX, any not of to-date the sites across trial. any are they did trial committee progress nor US. safety and conduct clinical as efforts meetings. issues we The pleased general continue our recommended and study by have with the our Overall, regarding Additionally, study made and reviews planned. meetings, two of conduct the being safety trial the that the concerns the data both we In completed safety committee identify
is finalized database completed. blinded, has all the been and will As when a and until the follow look of reminder, study on the forward to up ORCA-X further We locked. company evaluations providing until updates remain completion enrollment
enabling great progress non-clinical numerous have regulatory on NDA we Additionally, requirements. make to continued
and long chronic term required FDA toxicology completed studies. We submitted of the have to both
studies completed of that assessment reviewed expect a the are the the scientific first Also, be journals. In will important NDA near quarter, with we in FDA second and peer required the of all we published completed. one toxicology year, By for have special cytisinicline an study. also required required leading next protocol studies studies completion addition, non-clinical in two for we had carcinogenicity two
First, from superior compared and trial, and Achieve cytisinicline published quit safety to rates the for results ORCA-X tobacco placebo Phase research. X impressive nicotine was responses demonstrating in
X of instrumental in a we this taken reminder, administration a into that development. day and As milligram X study X forward the was the times selection Phase have dose
showing when Additionally cytisinicline rates improved the lower adverse of journal study to addiction. comparing efficacy and was in the New Zealand events CHANTIX RAUORA published
sharing coming in months additional the to from you expect efficacy when forward and with look We that analysis RAUORA, available.
as the leading in Finally, expenses our this Dr an Martell turn clinical appointment and XXXX. over to to March Achieve’s The and X in results. efforts. call me Jacobs. financial Dr. and leader Officer, medicine regulatory certified and like an discuss Board strengthens I'd addition and development Directors is duties, Martell having jump connection, the Board is Maybe Medical our with quarter of XX, Jacobs and the Dr well clinical for Board. time, an of regulatory our to quarter balance our Jacobs of Bridget Martell recent XXXX as Cindy cash President serves I'd as role, expertise. executive internal the issue appointment experienced new of operating on in as diversity, and announced Achieve current both we our and Dr. like both industry. At will provide Jerry her Jerry's first this her pharmaceutical Achieve’s update Chief in. and continue in Dr. to let so to addiction board to
restricted the were believe provide XX, to We XX, sufficient cash, million cash short million balance company's compared XXXX. cash $XX.X middle XXXX. runway in of cash is of as the equivalents, December investments term $XX.X our into March of to As
of $X.X of quarter same operating of net for increase in the Turning the a the Total to to company million million quarter of the XX, operations, as for same compared of XXXX. loss to million first loss for March quarter XXXX, to quarter net incurred expenses as $X million of $X statement the compared ended XXXX a $X.X XXXX. the
in highlighted March, and significantly development continue advancing and the excellent operating in during clinical middle through forward continue regulatory cytisinicline we operating as make ORCA-X expected progress interest momentum enrollment to first and on we the quarter, the remain call quarter in during were In In elevated XXXX, expenses on completion enrollment in we increased the our as anticipate year. the first of ORCA-X, the to required to in look process. execute this to of saw As We the in elevated trial closing, increased. expenses trial. our ORCA-X
the again of publication to potential prepared across data execute joining awareness continue on required That Thank NDA-enabling you we new audiences. expand Additionally, and remarks. us. for our activities to concludes key cytisinicline’s of
open to will Operator? now the We questions. line
